BioCentury This Week
Детали канала
BioCentury This Week
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
Недавние эпизоды
361 эпизодов
Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint
Gilead is acquiring Arcellx for $7.8 billion up front three years after forging a partnership with the biotech around a cell therapy for multiple myel...
Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA
As targeted protein degradation gains momentum, oral selective estrogen receptor degraders are emerging as one of its most advanced proving grounds. O...
Ep. 349 - Start-up Spotlight, Compounding Wegovy & Neuropysch
2025 marked the end of a four-year slide in series A financings for biotechs, with 144 biotechs raising an aggregate of $8 billion, up $1 billion from...
Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules
RNAi and exon-skipping therapies headline the list of regulatory and pivotal data catalysts in 2026, while new lipid-lowering mechanisms, modalities,...
Ep. 347 - Speeding China's Innovation. Plus: Neuro Catalysts and Newcos
New rules in China will accelerate the country’s cell and gene therapy sector by reshaping how investigator-initiated trials are conducted and commerc...
Ep. 346 - 2026 Public Markets Preview
The biotech bull is back, and buysiders believe this market has staying power for the first time in nearly five years. On a special episode of the Bio...
Ep. 345 - TAC to the Future. Plus: GSK Deal, MFN
Next-generation induced proximity technologies are coming of age after a decade of industry focus on PROTACs. On the latest BioCentury This Week podca...
Ep. 344 - JPM Momentum and Asia’s Hotbeds of Innovation
The J.P. Morgan Healthcare Conference kicked off this week with sunny skies over San Francisco and more financial momentum than the biotech industry h...
Ep. 343 - JPM Deals, Policy Outlook, Approval Trends
Riding the tailwind of a strong 2H25, the days leading up to biotech’s annual kickoff meeting in San Francisco delivered billions in capital raised an...
Ep. 342 - 2026 Biotech Kickoff
The New Year begins with biotech running along parallel storylines. There’s cause for optimism as the industry’s financing gears have begun to churn a...
Ep. 341 - BioCentury's '25-'26 Picks. Plus: BioMarin & Biotech ICYMI
This past year was an inflection point for biotech: The markets woke up, M&A and China had strong showings, drug development offered key trends, and n...
Ep. 340 - Obesity Data, Kymera & FDA Survey Results
Obesity readouts continue to be hot for biotech with new top-line data from both injectable and oral therapies pushing the boundaries on efficacy. On...
Ep. 339 - Biotech M&A, In Vivo CAR Ts & FDA Tumult
Fueled by cancer, obesity and cardiovascular deals, $1 billion-plus takeouts in biotech are at their highest level in a decade with three weeks to go...
Ep. 338 - Semaglutide’s Alzheimer’s Miss. Plus: Vaccine Policy, C> Funding
Novo Nordisk’s highly anticipated data for semaglutide in Alzheimer’s dashed hopes that the GLP-1 therapy could become a game changer in the disease....
Ep. 337 - FDA’s Moving Goalposts & China’s Innovation Arc
A baffling decision by FDA to issue a complete response letter for a pediatric medicine the medical community stood behind is just the latest example...
Ep. 336 - Cautious Optimism and M&A Momentum
There is cautious optimism around continued M&A momentum and the public equities markets as biotech heads into the New Year. On a special edition of t...
Ep. 335 - Neurology's Coming Inflection Point
Voyager CEO and former head of R&D at Biogen Al Sandrock is more optimistic than ever about the prospect of bringing clinically meaningful solutions t...
Ep. 334 - Pazdur’s New FDA Role, SITC & China RNAi
Richard Pazdur took the top job at FDA’s Center for Drug Evaluation and Research after receiving vows that he would be leading CDER free from politica...
Ep. 333 - Is This Korea’s Biotech Moment?
Today’s South Korean biotechs have a risk-on mentality, a willingness to partner, and strategies focused on globalization. On a special edition of the...
Ep. 332 - Obesity in Focus. Plus: What’s Next for FDA
With ObesityWeek yielding eye-catching amylin data and a bidding war that ran to $10 billion for Metsera, weight loss companies were center stage in b...
Ep. 331 - Metsera M&A Melee & Tidmarsh Ouster
Novo Nordisk’s unsolicited $8.5 billion bid for Metsera has thrown a wrench into Pfizer’s plans to return to the obesity race via its acquisition of t...
Ep. 330 - China's Innovation Moment
China is setting a new bar for the speed of clinical development and redefining the time it takes an asset to get to the clinic. On a special edition...
Ep. 329 - Novartis' $12B Avidity Buy. Plus: Base Editors
Novartis’ biggest deal in more than a decade gives the Swiss pharma three programs for muscular dystrophies that are close to the finish line. On the...
Ep. 328 - Brain Shuttles, GSK Q&A and FDA Vouchers
Next-generation platforms and technologies are getting closer to cracking one of biopharma’s biggest problems: delivering medicines, and mAbs in parti...
Ep. 327 - Where Gene & Cell Therapy Go Next With Evotec's Bernd Mühlenweg
It’s been a tough year for cell and gene therapy — patient deaths, high-profile companies pulling out of the space, and sour investment sentiment. But...
Ep. 326 - Market Outlook, Biosecure Returns, Biotech M&A
Biotech’s fourth quarter began with a familiar feeling, with indicators pointing toward an improving public market even as political and regulatory un...
Ep. 325 - Pfizer MFN Deal, New Trial Paradigm & Billion $ Fund
The short-term consequences for Pfizer from its “most favored nation” drug pricing deal with the White House are negligible, but the long-term effects...
Ep. 324 - Genmab, GSK and Drug Pricing
Genmab's $8 billion acquisition of multispecifics company Merus is the Danish biotech’s largest step toward marketing its own pipeline. On the latest...
Ep. 323 - Agentic AI: From New Targets to the Clinic
AI is bringing sweeping changes to drug development, from how targets are discovered to optimizing clinical trials to maximize an asset’s chance for s...
Ep. 322 - Takeaways from BioCentury Grand Rounds Europe
Is this the U.K.’s moment to capitalize on its biotech ecosystem? That was one of the primary themes discussed at the debut Grand Rounds — Europe conf...
Ep. 321 - Pfizer’s Obesity Play & U.K. in Focus
A takeout that could be worth as much as $7.3 billion has Pfizer back in the obesity drug development race. On the latest BioCentury This Week podcast...
Ep. 320 - U.K. Biotech, U.S.-China, Insmed
Merck's announcement that it is moving its R&D out of the U.K. highlights concerns about the country’s life sciences policies. On the latest BioCentur...
Ep. 319 - David Baltimore’s Legacy, Atlas Fund, MASH Pipeline and more
Molecular biologist and Nobel Prize winner David Baltimore made foundational contributions to the biopharma industry and was the essential figure behi...
Ep. 318 - Newco Takes on CV Risk. Plus: Disrupting Vaccines
Two veteran biotech leaders are launching a new company with ambitions in the cardiovascular disease space. On the latest BioCentury This Week podcast...
Ep. 317 - Biotech IPOs, FDA-Stealth & Patent Threat
There’s been a rare IPO filing on NASDAQ as LB Pharma looks to test the market during a year that has seen little activity among U.S. biotechs even as...
Ep. 316 - Trends in Pharma Deals
BioCentury’s third annual analysis of pharma company deals finds that bispecifics and degraders are in, cell and gene therapies are out, and China is...
Ep. 315 - China Speed: Data, Deals, First in Class
Dealmaking between Western and Chinese biopharmas has been one of the year’s bright spots, as a maturing biotech landscape in China converges with Wes...
Ep. 314 - Prasad, Lilly Obesity, Acadia & Biosecure
Phase III data from Lilly’s orforglipron in obesity fell short of investor expectations, but they appear to be enough to obtain approval and wide use....
Ep. 313 - Lessons from FDA's Prasad. Plus: What's next for Novo, Bayer
The ouster of Vinay Prasad after three months running FDA’s Center for Biologics Evaluation and Research could signal a reset is ahead for CBER. On th...
Ep. 312 - Biotech Progress Report
A handful of encouraging signals is cause for cautious optimism for biotech headed into the second half of the year — companies have been able to parl...